Mr Moyes was appointed to the board of directors in April 2025. Since April 2012, Mr. Moyes has also served on the board of directors of Puma Biotechnology, Inc. a public biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Mr. Moyes has been a member of the board of directors of Biocardia, Inc., a public cardiovascular regenerative medicine company, since January 2011. Mr. Moyes served as the Chief Financial Officer of Sera Prognostics, Inc., a public commercial-stage biotechnology company focused on improving maternal and neonatal health through innovative biomarker approaches, from March 2020 to June 2023. Mr. Moyes previously served as a member of the board of directors of Achieve Life Sciences, Inc., a public specialty pharmaceutical company, from August 2017 to May 2023; Predictive Technology Group, Inc., a public molecular diagnostics and regenerative medicine company, from February 2019 to December 2019; Osiris Therapeutics, Inc., a public bio-surgery company, from May 2006 until December 2017; and Amedica Corporation (now SINTX Technologies, Inc.), a public orthopedic implant company, from November 2012 to August 2014. He served as Chief Financial Officer of Amedica from October 2013 to August 2014. From May 2008 through July 2009, Mr. Moyes served as Chief Financial Officer of XDx (now CareDx), Inc., a privately held molecular diagnostics company. Prior to that, Mr. Moyes served as Chief Financial Officer of Myriad Genetics, Inc., a public healthcare diagnostics company, from June 1996 until November 2007, and as its Vice President of Finance from July 1993 until July 2005. From 1991 to 1993, Mr. Moyes served as Vice President of Finance and Chief Financial Officer of Genmark, Inc., a privately held genetics company. Mr. Moyes held various positions with the accounting firm of KPMG LLP from 1979 through 1991, most recently as a Senior Manager. He holds an M.B.A. from the University of Utah, a B.A. in economics from Weber State University, and is formerly a Certified Public Accountant. Mr. Moyes also served as a member of the Board of Trustees of the Utah Life Science Association from 1999 through 2006. Mr. Moyes was nominated to serve as a director because his extensive background in finance and accounting and his experience in the context of the life sciences industry enable him to make significant contributions to the Board.
What is Jay M. Moyes' net worth?
The estimated net worth of Jay M. Moyes is at least $123.35 thousand as of June 12th, 2026. Mr. Moyes owns 58,322 shares of Sintx Technologies stock worth more than $123,351 as of October 7th. This net worth evaluation does not reflect any other investments that Mr. Moyes may own. Learn More about Jay M. Moyes' net worth.
How do I contact Jay M. Moyes?
Has Jay M. Moyes been buying or selling shares of Sintx Technologies?
Jay M. Moyes has not been actively trading shares of Sintx Technologies over the course of the past ninety days. Most recently, on Monday, February 23rd, Jay M. Moyes bought 1,000 shares of Sintx Technologies stock. The stock was acquired at an average cost of $2.91 per share, with a total value of $2,910.00. Following the completion of the transaction, the director now directly owns 4,000 shares of the company's stock, valued at $11,640. Learn More on Jay M. Moyes' trading history.
Who are Sintx Technologies' active insiders?
Are insiders buying or selling shares of Sintx Technologies?
During the last twelve months, Sintx Technologies insiders bought shares 8 times. They purchased a total of 101,292 shares worth more than $378,064.28. The most recent insider tranaction occured on March, 2nd when Director
Christopher Michael Lyons bought 7,534 shares worth more than $21,848.60. Insiders at Sintx Technologies own 4.1% of the company.
Learn More about insider trades at Sintx Technologies. Information on this page was last updated on 3/2/2026.
